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Purpose: To describe the drugs used to treat venous throm-
boembolism (VTE) and to review particular aspects of the 
management (elastic stockings, thrombolysis, thrombectomy, 
vena cava filter).
Source: Our review of the literature is focused on consensus 
documents and recent large randomized trials.
Principal findings: Subcutaneous low molecular weight hepa-
rins (LMWH) have been shown to be both safe and effective 
for the initial treatment of VTE and have largely replaced 
unfractionated heparin, unless there is a contraindication to 
LMWH such as severe renal insufficiency. Low molecular weight 
heparins or unfractionated heparin are usually administered for 
five to seven days. Treatment is gradually switched from heparin 
to oral vitamin K antagonists (VKA) which are usually started 
the same day as heparin. The duration of oral anticoagulation 
must be tailored to the individual patient according to the pres-
ence of reversible or continuing risk factors. In patients with 
active cancer, long-term treatment of VTE with LMWH has 
been shown to be more effective than oral anticoagulation and 
is recommended for the first three to six months of long-term 
anticoagulant therapy as an alternative approach to VKA. Elastic 
stockings are recommended because they have been shown 
to prevent postthrombotic syndrome. Thrombolysis is, usually, 
not justified for the treatment of deep venous thrombosis, but 
is used in cases of massive pulmonary embolism with arterial 
hypotension and/or shock. Vena cava filter placement is mainly 
indicated in patients with a proximal deep venous thrombosis 
and an absolute contraindication to anticoagulation.
Conclusions: The initial management of patients with acute 
VTE has largely been simplified due to the use of LMWH. Early 
conversion to VKA is recommended for the great majority of 
patients. New agents, such as anti-Xa or oral thrombin inhibi-
tors, are promising alternatives to heparins or VKA. 
Objectif : Présenter les médicaments utilisés pour traiter la mala-
die thromboembolique veineuse (MTEV) et revoir des aspects par-
ticuliers de la thérapie comme les bas élastiques, la thrombolyse, 
la thrombectomie et le filtre cave.
Source : Revue de documents de consensus et de grandes études 
récentes.
Constatations principales : Les héparines de bas poids molécu-
laire (HBPM) sont sûres et efficaces comme traitement initial de 
la MTEV et remplacent largement l’héparine non fractionnée, à 
moins d’une contre-indication à l’HBPM comme l’insuffisance 
rénale sévère. Les HBPM ou l’héparine non fractionnée sont habi-
tuellement administrées pendant cinq à sept jours. Puis, on passe 
graduellement de l’héparine à la prise orale d’antagonistes de la 
vitamine K (AVK), débutés en général le même jour que l’héparine. 
La durée de l’anticoagulation orale doit être adaptée au patient en 
fonction de facteurs de risque réversible ou continu. Dans les cas 
de cancer actif, le traitement  de la MTEV avec l’HBPM s’est mon-
tré plus efficace que l’anticoagulation orale et il est recommandé 
pour les trois à six premiers mois de traitement. Les bas élastiques 
sont recommandés pour prévenir le syndrome post-thrombotique. 
La thrombolyse n’est pas habituellement justifiée pour traiter la 
thrombose veineuse profonde, mais est utilisée en cas d’embolie 
pulmonaire massive avec hypotension et/ou choc artériels. La 
mise en place d’un filtre cave est principalement indiquée chez les 
patients souffrant de thrombose veineuse profonde proximale chez 
qui l’anticoagulation est une contre-indication absolue.
Conclusion : Le traitement initial des patients atteints de MTEV 
a été grandement simplifié avec l’usage de l’HBPM. Le passage 
précoce aux AVK est recommandé pour la grande majorité des 
patients. De nouveaux médicaments comme les anti-Xa ou les 
inhibiteurs de la thrombine oraux, sont des équivalents pro- 
metteurs des héparines ou des AVK.
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I
N most cases, pulmonary embolism (PE) is 
secondary to deep venous thrombosis (DVT); 
moreover, asymptomatic PE is observed in 40% 
of patients presenting with proximal DVT when 
systematic lung scintigraphy is performed.1 Therefore 
DVT and PE may be considered as the same disease 
and will be treated together under the common term 
of venous thromboembolism (VTE). The treatment 
(anticoagulation) is also essentially the same.2 In this 
review we will first discuss the drugs (old and new) 
and then some particular aspects of the manage-
ment of VTE (early ambulation and elastic stockings, 
thrombolysis, thrombectomy, embolectomy, vena cava 
filter). The management of anticoagulated patients 
who require surgery and for over-anticoagulated 
patients, as well as the problem of heparin-induced 
thrombocytopenia are dealt with elsewhere. 
A. Anticoagulant treatment
Venous thromboembolism is a medical emergency 
and the first step, in most patients, is to administer 
heparin immediately with an early switch to vitamin 
K antagonists (VKA). Three options are available for 
the initial treatment of VTE: low-molecular weight 
heparins (LMWH), iv unfractionated heparin (UFH) 
or sc UFH. 
1. Unfractionated heparin and LMWH
Treatment of VTE starts with heparins. The advan-
tages of LMWH over UFH are summarized in Table 
I. Although LMWH have more favourable pharma-
cological properties than UFH, clinical studies have 
not shown important differences concerning their 
efficacy or safety, although it is possible that the risk 
of mortality is decreased with LMWH.2,3 Due to their 
simplicity of administration, LMWH have become the 
drug of choice in the initial treatment of VTE. Indeed, 
LMWH provide a higher level of comfort for the 
patient, their use is less time consuming for nurses and 
laboratory technicians since no laboratory controls are 
required. They carry a lower risk of heparin-induced 
thrombocytopenia and osteopenia, two adverse events 
that may be observed if the treatment lasts more than 
the usual five days. Moreover, LWMH are associated 
with cost savings since they allow early hospital dis-
charge and home therapy.
2. Is there still a place for unfractionated heparin?
The difficulties of attaining therapeutic concentrations 
with UFH are well known. Unfractionated heparin 
has an unpredictable dose response and a narrow 
therapeutic window. For example, an audit conducted 
in three North American hospitals has shown that 60% 
of patients did not have a therapeutic activated par-
tial thromboplastin time (aPTT) in the first 24 hr of 
treatment and that 30 to 40% of patients did not have 
therapeutic anticoagulation during the first four days.4 
Most often the doses of UFH are subtherapeutic, phy-
sicians being afraid of hemorrhagic complications. 
If LMWH are generally given in cases of DVT, 
their use is not generalized in cases of PE, despite 
the results of clinical studies.5,6 This is particularly 
true for severe PE where UFH is still preferred. The 
main contraindication to LMWH is renal insufficiency 
(a particular consideration in elderly patients). For 
very young children and for pregnant women, some 
physicians still prefer to give UFH. In unstable situa-
tions and/or when an invasive procedure is planned, 
UFH is preferred due to its shorter half-life (approxi-
mately one hour as compared to about four hours for 
LMWH). Finally, when VTE occurs soon after a sur-
gical procedure and/or when a bleeding risk persists, 
UFH is also favoured. 
3. Unfractionated heparin: administration and control
Once a diagnosis of VTE is suspected, an initial iv 
bolus of 80 UI·kg–1 of UFH should be administered. 
An infusion of UFH is initiated (18 UI·kg–1·hr–1) and 
a control of the aPTT should be obtained four hours 
after beginning the infusion. The aim is to obtain 
a prolongation of the aPTT two to three times the 
control value. It is important to realize that the aPTT 
depends on reagents and devices used. Therefore 
therapeutic intervals should be defined by each labo-
ratory. When the target level is obtained, a daily con-
trol is necessary. Changes can be made according to 
a nomogram.7 Controls are mandatory; indeed the 
incidence of early recurrent VTE is correlated with 
failure to obtain an effective anticoagulation rapidly.2,7 
Moreover, the majority of bleeding complications 
occur at the early stage of the treatment.2,3,8
TABLE I  Main characteristics of UFH and LMWH
 UFH LMWH
−  Mean molecular weight 15000 5000
−  Anti-Xa/anti-IIA ratio 1 2–4
−  Plasma protein binding +++ +
−  Binding to endothelial cells,  +++ + 
    macrophages and platelets 
−  Renal clearance (+) +++
−  Plasma half-life highly variable less variable
 1–4 hr 3–6 hr
UFH = unfractionated heparin; LMWH = low molecular weight 
heparins.
S82 CANADIAN JOURNAL OF ANESTHESIA
It is possible to check UFH activity by tests other 
than the aPTT. One of the most frequently performed 
assays is the measure of anti-Xa activity. For example, 
some patients require very high doses of UFH to 
reach a therapeutic aPTT, often because of an impor-
tant inflammatory syndrome. For these patients it is 
preferable to measure anti-Xa levels which, probably, 
are a better reflection of the degree of anticoagulation 
and thus avoid the administration of excessive doses of 
UFH.9 A patient is considered to be well anticoagu-
lated when the anti-Xa activity ranges between 0.3 and 
0.7 IU·mL–1 by the amidolytic assay. 
4. Subcutaneous unfractionated heparin: administra-
tion and control
Unfractionated heparin can also be given by the sc 
route which is as efficacious as its iv administration. 
Doses to be given are comparable or slightly higher 
than when UFH is given iv. Usually, controls are 
performed four to six hours after the sc injection, 
which corresponds to the peak activity of UFH in 
the blood.10 Target values are in the range of those 
expected in the case of iv administration. Another 
possibility is to check the aPTT just prior to the next 
injection, in order to evaluate residual UFH activity. 
In this case, the aPTT should be approximately 1.5 × 
the control, which corresponds to an anti-Xa activity 
close to 0.15 IU·mL–1.
5. Low molecular weight heparin: administration and 
control
Because of their favourable pharmacological charac-
teristics, LWMH are administered according to the 
patient’s weight, without need for a bolus or laborato-
ry control.11 The simplicity of treatment with LMWH 
avoids hospitalization for patients with uncomplicated 
lower limb DVT.12,13 However it is important to note 
that one third of patients eligible to home treatment 
in one study12 and two thirds in a second study13 were 
excluded. Outpatient treatment is possible if ambula-
tory care is well organized.
Low-molecular weight heparin can be adminis-
tered in one or two daily injections.14 Due to their 
renal clearance, LMWH are usually contraindicated 
in patients having a creatinine clearance below 30 
mL·min–1. In some situations (hemorrhagic or throm-
botic complications under LMWH, extremes of age or 
weight, pregnant women), laboratory controls may be 
performed. Anti-Xa activity is measured, usually three 
to five hours after the injection.15 If the LMWH is 
given twice daily, the target concentration will be 0.5–
1.0 IU·mL–1 anti-Xa activity while, if it is administered 
once a day, the target concentration will be 0.8–1.6 
IU·mL–1 anti-Xa activity. As the aim is to detect an 
overdose due to possible accumulation of the LMWH, 
measurement of anti-Xa activity is recommended after 
three injections.15 
Various LMWH exist and the doses and the target 
interval may be different for each LMWH (Table II). 
For example, for tinzaparin, the peak anti-Xa activity is 
0.8 IU·mL–1 whereas for nadroparin, another LMWH 
also administered once a day, the peak anti-Xa activity 
is 1.3 IU·mL–1.15 As for UFH, platelet counts should 
be monitored if LMWH are given for more than five 
days.
6. Vitamin K antagonists 
Various VKA are available and some of their character-
istics are presented in Table III.
Treatment is usually started the same day as hepa-
rin, without a loading dose. Four to six days are usually 
necessary to obtain two international normalized ratio 
(INR) of the prothrombin time within the therapeutic 
range (2.0–3.0) and therefore there is an overlap of 
the two drugs for a few days. The minimal duration 
of heparin therapy should be five days. When the tar-
get INR is obtained at least twice at an interval of 24 
hr, INR controls may be less frequent. It is generally 
advised to control the INR once a week during the 
first month of treatment, then monthly thereafter.
If the patient is receiving other medications, pos-
sible drug interactions should be considered. It should 
be kept in mind that any modification of alternate 
treatments (change of drug or any change of dosage 
of a drug already given) may modify the interaction 
with VKA and therefore change the INR.16 Other 
factors will influence anticoagulation, mainly liver 
and renal diseases, fever, hyperthyroidism as well as 
food. The so-called “VKA resistance” is often due 
to a poor understanding of anticoagulation by the 
patient. Bleeding risk depends on numerous fac-
tors such as patient compliance, concomitant intake 
of other drugs, intensity and variability of the INR, 
comorbidities, age more than 80 yr and length of 
treatment.16,17
TABLE II  Doses of LMWH for the treatment of venous 
thromboembolism
LMWH Recommended doses
Enoxaparin 100 U (1 mg·kg–1) twice daily
Nadroparin 85 U·kg–1 twice daily or 170 U·kg–1 once daily
Dalteparin 100 U·kg–1 twice daily
Tinzaparin 175 U·kg–1 once daily
LMWH = low molecular weight heparins.
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The optimal duration of anticoagulation has been 
the object of several studies and debate.18–26 For distal 
DVT, six weeks may be enough although the seventh 
American College of Chest Physicians Conference 
on Antithrombotic and Thrombolytic therapy pub-
lished recently in Chest2 proposes three months of 
anticoagulation for a symptomatic DVT confined to 
the calf veins. For a proximal DVT or a PE with an 
identifiable cause (for example after hip arthroplasty), 
anticoagulation is required for three months after a 
first episode. When VTE is considered idiopathic (no 
obvious triggering factor), anticoagulation should last 
at least six months, or longer if the risk of bleeding 
is low. A longer duration of anticoagulation should 
be contemplated when the risk factor is permanent 
(cancer for example), when a severe thrombophilia 
(e.g., antiphospholipid antibodies, antithrombin defi-
ciency, combined factor V Leiden and prothrombin 
G20210A mutations) is detected or when there is 
recurrence of VTE. In these situations the treatment 
should be individualized. Two studies have evaluated 
specifically whether, after a minimum of three months’ 
treatment with a target INR ranging between 2.0 and 
3.0, an INR maintained subsequently between 1.5 and 
2.0 retains the antithrombotic benefit while decreas-
ing the risk of bleeding complications.25,26 Conflicting 
results were reported. For some patients indefinite 
anticoagulant therapy should be considered; however 
the risk-benefit of continuing such a treatment should 
be reassessed periodically.
Recent studies suggest that D-dimer levels and 
ultrasonography after withdrawal of anticoagulation 
may be useful in estimating the risk of recurrence of 
VTE.27–29 Increased D-dimer levels were associated 
with a higher risk of subsequent recurrence. However, 
it is not yet known whether D-dimer levels or residual 
venous thrombosis have a role in adjusting the dura-
tion of oral anticoagulant therapy. Clinical trials are 
ongoing to evaluate this possibility.
7. Low molecular weight heparin for the long-term 
treatment of patients with cancer
Long-term treatment with adjusted doses of a VKA 
is highly effective for preventing recurrent VTE in 
patients free of malignancy. This approach is less effec-
tive in patients with active cancer and is associated 
with a higher risk of bleeding than in patients without 
malignancy.30 Two recent randomized clinical trials 
have assessed the potential benefit of long-term treat-
ment of acute VTE with sc LMWH as an alternative 
approach to VKA in patients with cancer and acute 
DVT or PE.31,32 In a study including 676 patients, 
sc dalteparin alone for six months (200 IU·kg–1 once 
daily for one month, followed by 150 IU·kg–1 once 
daily for five months) was compared with dalteparin 
200 IU·kg–1 body weight sc once daily for five to 
seven days, followed by oral treatment with VKA for 
six months (target INR ranging from 2.0 to 3.0).31 
During the six-month study period, recurrent VTE 
occurred in 15.7% of patients who received the VKA 
treatment, compared with 8.0% of those who received 
a LMWH (dalteparin) alone (P = 0.002). Rates of 
major bleeding were similar between the two groups. 
In the second study, Meyer et al. compared enoxapa-
rin sodium (1.5 mg·kg–1 once daily) with VKA given 
for three months in 146 patients.32 The rate of major 
outcome event (defined as major bleeding or recur-
rent VTE within three months) was 21.1% in patients 
assigned to receive VKA compared with 10.5% in 
patients assigned to receive enoxaparin (P = 0.09). 
The trend in favour of enoxaparin was accounted for, 
mainly, by a higher rate of major bleeding in the VKA 
group (16% vs 7.0%, P = 0.09). These studies suggest 
that prolonged LMWH therapy is more effective and 
possibly safer than oral anticoagulation. Recently, the 
American College of Chest Physicians consensus con-
ference on antithrombotic therapy strongly recom-
mended LMWH for the first three to six months of 
long-term anticoagulant therapy in cancer patients.2
8. New anticoagulants
Several new antithrombotic agents have been devel-
oped in recent years. Until now, only the efficacy and 
safety of fondaparinux and ximelagatran in the treat-
ment of established VTE have been evaluated in large 
phase III trials. 
FONDAPARINUX
Fondaparinux is a synthetic analogue of the natu-
rally occurring pentasaccharide sequence and, like 
UFH and LMWH, acts as an anticoagulant by 
binding antithrombin. Fondaparinux catalyses fac-
tor Xa inhibition by antithrombin, but has no effect 
TABLE III  Main characteristics of vitamin K antagonists
VKA Protein  Plasma  Duration of  
 binding half-life (hr) action (hr)
Coumarin derivatives 
−  warfarin 97% 35–45 96–120
−  acenocoumarol 97% 8–9 36–48
−  phenprocoumon 97% 140–160 170–240
Indane-dione derivatives
−  fluindione 95% 30 48–72
VKA = vitamin K antagonists.
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on the rate of thrombin inactivation. Fondaparinux 
has an excellent bioavailability after sc injection and 
is administered once a day. In an open label study, 
2,213 patients with symptomatic PE were randomly 
assigned to receive either fondaparinux (5.0, 7.5 or 
10 mg in patients weighing less than 50, 50 to 100 
or more than 100 kg respectively) sc once daily or a 
continuous infusion of UFH for at least five days fol-
lowed by VKA for six months.33 The study showed 
that the incidence of VTE recurrence at three months 
was 3.8% and 5.0% in the fondaparinux and the UFH 
group respectively, demonstrating non-inferiority of 
fondaparinux/VKA vs UFH/VKA. The same regi-
men of fondaparinux was compared with enoxaparin 
1 mg·kg–1 twice daily for at least five days followed by 
VKA for three months in a randomized double-blind 
trial including 2,305 patients with acute DVT.34 The 
study showed that during a three-month follow up, 
3.9% of the fondaparinux-treated patients had symp-
tomatic recurrent VTE compared with 4.1% of the 
enoxaparin-treated patients, demonstrating that once-
daily fixed-dose fondaparinux was at least as effective 
as twice-daily body-weight adjusted enoxaparin. In 
both studies, the rates of major bleeding did not differ 
significantly between groups. Fondaparinux is particu-
larly interesting because of its synthetic origin and the 
lack of heparin-induced thrombocytopenia reported 
until now. 
XIMELAGATRAN
Ximelagatran, which can be given orally, is the prodrug 
of melagatran. Melagatran is a synthetic low molecu-
lar weight competitive thrombin inhibitor. This new 
agent produces a more predictable anticoagulant 
response than heparin so that no coagulation moni-
toring is required. Moreover, in comparison with oral 
VKA, food or alcohol do not interfere with this new 
agent and very few drug interactions with drugs have 
been demonstrated.35 In a randomized double-blind 
study, 1,233 patients with VTE who had completed 
six months of standard anticoagulation therapy were 
randomly assigned to extended secondary prophy-
laxis with ximelagatran 24 mg twice a day vs placebo 
for 18 months without monitoring of coagulation.36 
The study showed that, compared with placebo, 
ximelagatran significantly reduced the cumulative risk 
of recurrence from 12.6% to 2.8% over 18 months. 
Bleeding rates did not differ significantly between 
the two groups. Ximelagatran-treated patients were 
more likely to have increases in serum alanine ami-
notransferase greater than three times the upper 
limit of normal compared to placebo (6.2% vs 1.2%). 
Elevations in liver enzymes mostly occurred between 
two and six months of treatment and most of them 
resolved either spontaneously or after discontinuation 
of treatment. The efficacy and safety of ximelagatran 
in the treatment of acute DVT has been evaluated 
in another randomized double-blind study including 
2,491 patients.37 Patients were randomly assigned 
to receive either ximelagatran 36 mg twice a day or 
enoxaparin 1 mg·kg–1 for at least five days followed by 
warfarin for six months. The study showed that the 
cumulative risk of VTE recurrence at six months was 
2.1% and 2.0% in the ximelagatran and the enoxaparin 
group respectively, demonstrating non-inferiority of 
ximelagatran vs enoxaparin/warfarin. The incidence 
of major bleeding did not differ significantly between 
the two groups. The increase of liver enzymes was, 
again, a matter of very serious concern, which finally 
leads to withdrawal of the drug.
In conclusion, these two drugs have been shown 
to be at least as effective and safe as standard therapy 
in the initial treatment of VTE Ximelagatran has been 
withdrawn from the market but several new anti-Xa or 
anti-thrombin inhibitors are under evaluation. Cost-
effectiveness analyses will be required to determine 
the role of these new agents in this clinical setting. 
B. Other treatments
1. Compression elastic stockings 
Within three years after an episode of DVT of the 
lower extremities, more than 30% of patients develop 
pain, swelling, skin pigmentation and venous dilata-
tion (and, eventually, leg ulceration), all complications 
usually referred to as postthrombotic syndrome.38
Elastic compression stockings with a pressure of 30 
to 40 mmHg at the ankle have been shown to be cru-
cial to prevent postthrombotic syndrome. In two ran-
domized studies, patients with acute proximal DVT 
were assigned to wear or not wear compression elastic 
stockings.39,40 In both studies, compression stock-
ings reduced the rate of postthrombotic syndrome by 
approximately 50%. 
Elastic bandages should be used during the first 
days in combination with leg elevation and ambula-
tion in order to prevent stasis. When edema stabilizes, 
compression stockings are prescribed. The stockings 
will have to be worn as long as the edema persists. 
Ideally stockings should be worn at least two years.39 
2. Thrombolysis 
Thombolysis (as well as thrombectomy) has been 
recommended for the initial treatment of DVT, 
based on the assumption that earlier vein patency will 
preserve venous function and therefore decrease the 
risk of postthrombotic syndrome. However, the rate 
de Moerloose et al.: TREATMENT OF VENOUS THROMBOEMBOLISM  S85
of clinically relevant postthrombotic sequelae does 
not appear to differ from that of patients receiving 
conventional anticoagulation. Therefore, in case of 
DVT, systemic thrombolysis is usually not justified. 
Indeed, this treatment carries a risk of major bleeding 
which is not justified in the case of a non-fatal disease. 
However, in very rare cases such as patients presenting 
with phlegmasia cerulea dolens, thrombolysis can be 
considered. Local thrombolysis may, possibly, provide 
some benefit but the place of this labour-intensive 
approach in the management of VTE remains to be 
established.41
For most patients with PE, systemic thrombo-
lytic therapy is not recommended. However in 
selected patients, thrombolysis can be beneficial.42,43 
Thrombolysis is used for massive PE with arte-
rial hypotension (< 100 mmHg) and/or a shock. 
Hemodynamically stable patients with acute PE and 
echocardiographic abnormalities (right ventricular 
dysfunction) and/or significant arterial hypertension 
might also benefit from thrombolysis.44 However, 
the use of thrombolytic agents in this setting remains 
controversial.2 In a randomized study, 256 patients 
with acute PE and pulmonary hypertension or right 
ventricular dysfunction (but without arterial hypoten-
sion or shock) were assigned to receive either heparin 
plus 100 mg of alteplase or heparin plus placebo 
over a period of two hours.45 The study showed that 
alteplase given in conjunction with heparin could 
prevent clinical deterioration requiring escalation of 
treatment. However, no difference between both 
treatment groups was observed in clinically relevant 
outcomes such as recurrent non-fatal or fatal PE. 
Further studies are required to document a clinically 
relevant improvement with thrombolytic therapy in 
these patients. 
The local administration of thrombolytic therapy 
via a catheter is not recommended. 
Although often relative, contraindications to throm-
bolysis should be observed. Contraindications should 
be balanced against the patient’s clinical status as well 
as the patient’s prognosis. For example, if the patient 
is treated with VKA, it is possible to give a preparation 
of prothrombin complex concentrate which allows 
normalization of the INR within a few minutes.
Thrombolysis is initiated via a peripheral vein, 
since there is no clear advantage to administration of 
a thrombolytic agent in the pulmonary artery. Several 
agents are available: streptokinase (loading dose of 250 
000 UI in 20 min, followed by a continuous infusion 
of 100 000 UI·hr–1 during 12 to 24 hr), urokinase 
(loading dose of 4400 UI·kg–1 in ten minutes, fol-
lowed by a continuous infusion of 4400 UI·kg–1·hr–1 
during 12 to 24 hr) or alteplase (50 mg·hr–1 during 
two hours, for a total of 100 mg). Various other pro-
tocols exist. At the end of the infusion of alteplase, 
heparin (1000 UI·hr–1) is started and anticoagulation 
is adjusted according to the aPTT.45 For streptoki-
nase or urokinase, heparin is usually begun when the 
fibrinogen level is above 1.0 g·L–1 and the aPTT less 
than twice the control value. 
3. Thrombectomy and embolectomy
Both are seldom indicated. A surgical thrombectomy 
may be considered in case of suspended iliac DVT, 
and an embolectomy can be performed in case of car-
diorespiratory arrest or pulmonary hypertension with 
fresh emboli. The decision to perform such a proce-
dure in a severely ill patient is extremely delicate and 
should be individualized. The decision will rely, espe-
cially, on the evolution of the patient under medical 
treatment, on the contraindications to thrombolysis, 
on the localization of clots as well as on the surgical 
team’s experience.46 Various iv catheter systems have 
been developed over the years to allow the division of 
clots into fragments and their aspiration; such non-
surgical embolectomies might represent an interesting 
option in some patients.
4. Vena cava filters
A study has shown the limited utility of definitive vena 
cava filters in case of DVT.47 The main indication is the 
presence of a proximal DVT with an absolute contra-
indication to anticoagulants (or a bleeding complica-
tion secondary to anticoagulation). Other indications 
may be considered such as well documented recurrent 
episodes of VTE under therapeutic anticoagulation. 
Finally, patients with postembolic chronic cor pulmo-
nale (any recurrence might be lethal), patients having 
undergone a recent surgical embolectomy for acute 
PE as well as those having had a thrombo-endarter-
ectomy should be considered candidates for this form 
of treatment. 
Conclusion
Anticoagulant treatment has demonstrated its efficacy 
to prevent recurrent episodes of VTE. New agents, 
such as anti-Xa or oral thrombin inhibitors, are prom-
ising alternatives for heparins or VKA. As far as other 
treatments are concerned, the most important are the 
systematic use of elastic stockings in case of DVT and, 
possibly, the administration of thrombolytic agents in 
case of massive PE. Vena cava filters are mainly indi-
cated for patients with a proximal DVT and a contra-
indication to anticoagulation. 
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